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Abstract
Introduction and hypothesis Stress urinary incontinence
(SUI) is common, impacts women’s quality of life, and
generates high costs. Physiotherapy is the first-line therapy,
and if it fails, suburethral slings are the gold standard in SUI
surgery. Bulking agents injected periurethrally might be a
beneficial alternative, but there is a paucity of data on bulking
therapy. The aim of this study was to prospectively analyze the
efficacy and safety of bulking agents in the setting of a tertiary
referral center.
Methods In the last 13 years, 514 elderly women with SUI
were treated by injection therapy with either collagen (Con-
tigen®), hyaluronic acid (Zuidex®), ethylene vinyl alcohol
(Tegress®), or polyacrylamide hydrogel (Bulkamid®). Sub-
jective and objective outcome was recorded at the 12-month
postoperative appointment using the King’s Health Question-
naire, visual analogue scale (VAS) describing their inconti-
nence severity, standardized pad test, and urethral pressure
profile.
Results Demographic data were equally distributed in all
four groups of agents used. Sixty-one patients were lost to
follow-up (10.6 %). Statistically significant changes were
found for maximum urethral closure pressure (MUCP), pad
weight, and VAS before and after bulking for the four agents
used. Pad test was negative in 73.2 % of patients after bulking
therapy. Subjective assessment showed improvements in gen-
eral health and role limitations. The overall complication rate
was low for all agents.
Conclusions This study shows improvement in incontinence
after bulking therapy according to subjective and objective out-
comes in an elderly population. In contrast to earlier reports, side
effects due to injections were few and mild. We can advocate
bulking therapy for treating SUI, as it is simple, safe, and shows
both objective and subjective improvement and relief.
Keywords Bulking agent . Bulking therapy . Geriatric
patients . Stress urinary incontinence
Introduction
Involuntary urine loss during coughing, sneezing, physical
exertion, or sudden changes of position characterize stress
urinary incontinence (SUI) caused by either sphincter ab-
normalities and/or urethral hypermobility [1, 2]. SUI, with
its high socioeconomic burden and negative influence on
women’s quality of life (QoL), is a common problem, with
approximately 35 % of women >18 years suffering from
involuntary loss of urine; at the age of 60 years, the rate rises
to 45 % in Europe [3]. Annual costs related to urinary
incontinence (UI) are estimated to be $27.8 billion in the
USA [4], and 359–655 Euros per patient treated in European
countries [5]. Treating incontinence might improve QoL and
cut these costs significantly.
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The first treatment step is pelvic floor rehabilitation [6],
followed by surgery if physiotherapy fails. As for surgery,
suburethral slings are as effective as colposuspension, with
lower perioperative morbidity, and are the gold standard in
patients with SUI, displaying high and long-term cure rates
[7, 8]. However, there is a need for alternative therapeutic
approaches in patients with significant comorbidities; in wom-
en who are unwilling to undergo surgery because of its asso-
ciated risks, pain, and recovery; in patients with recurrent SUI;
and in women in whom surgical options are limited (e.g.,
postoperatively or after irradiation) [9–14]. The study reported
here focuses on injection therapy with bulking agents, as this
technique may be considered as a first-line treatment option in
selected patients [11].
There is a paucity of data comparing bulking agents, results
of studies describing the efficacy of bulking agents are incon-
sistent [10, 15]. Hence, the choice of substance still depends
on safety considerations, ease of use, availability, and physi-
cian preference, as there is no strong evidence that one agent is
superior to the other [11]. Despite the theoretical advantages
of injection therapy, the latest Cochrane review from 2007
concluded that a lack of sufficient data on bulking agents
impeded creation of a meta-analysis [10]. The paucity of
long-term follow-up and health economic data, as well as
the finding of a possible placebo effect (improvement in pad
weight after saline injections), were further points of criticism
in the review [10]. However, another aspect was the lack of a
comparison between treatment with bulking agents and phys-
iotherapy [10], which was made redundant recently, as bulk-
ing seems to be more effective than pelvic floor training [16].
The Cochrane review concludes that limited data suggest
surgery to be objectively superior to bulking; however, as
patients are equally satisfied with either option, and regarding
the few side-effects of bulking therapy, the latter is considered
to be a reasonable first-line option [10].
Aim of this study was to analyze the efficacy and safety
of bulking agents in the setting of a tertiary-referral-center
prospectively.
Materials and methods
Between December 1999 and January 2012, 514 elderly
women with SUI or mixed urinary incontinence (MUI) were
treated by injection therapy with either glutaraldehyde cross-
linked bovine collagen (Contigen®), hyaluronic acid/dextra-
nomer copolymer (Zuidex®), ethylene vinyl alcohol
(Tegress®), or polyacrylamide hydrogel (Bulkamid®) in the
UniversityWomen’s Hospital, Department of Urogynecology,
Bern, Switzerland. Choice of bulking agent was dependent
upon substance availability and patient allergy to collagen.
Demographic data, including age, body mass index (BMI),
previous incontinence operations, number of injections and
perioperative data were noted. The study was approved by the
local ethical committee, and all patients gave informed con-
sent to participate.
The King’s Health Questionnaire (KHQ) assesses QoL and
is widely used in patients with incontinence [17]. It is validat-
ed in several languages, including German [18]. The ques-
tionnaire deals with the domains general health perception,
role limitation (e.g., household, cleaning, shopping), physical
and personal limitation (walking, sports, travel, social life,
relationship, sex, family life), emotions (depressed, anxious,
nervous, feeling bad about oneself), sleep (feeling worn out,
tired), and incontinence impact (pad usage, need to change
underwear, restrict drinking, fear bad smells). Moreover, blad-
der problems are specified in the KHQ as questions for fre-
quency symptoms, nocturia, urgency, stress incontinence
episodes, coital incontinence, urinary tract infections, and
bladder pain exist. The scores for each domain range from 0
to 5 and 1 to 5, respectively, are added up, and a change of at
least five points is considered significant [18]. Subjective
outcome was further assessed by patients judging their incon-
tinence severity on a visual analogue scale (VAS). The VAS is
a validated tool for assessing health and satisfaction in
patients, for investigating pain, and for measuring attitudinal
attributes and QoL [19]. Additionally, as objective measure-
ments, a standardized 2-h in-office pad test according to
International Continence Society (ICS) recommendations
[20] was performed, and residual urine was measured using
transabdominal ultrasound. Additionally, urethral pressure
profile was measured using microtip catheters.Microtip meas-
urements were taken in the 45° upright position with the
patient at rest and at bladder capacity using an 8-F double
microtip transducer (Gaeltec®) withdrawn at 1 mm/s and the
transducer orientated in the 3 o’clock position, with one
transducer inside the bladder and the second distally posi-
tioned in the urethra. Three consecutive measurements were
taken for each patient and the average calculated.
Before and following intervention, the presence of urinary
tract infections was excluded using dipstick screening, and
infections or bacteriuria was treated. For the injection proce-
dure, women were placed in the lithotomy position, 10–20 ml
of 1 % lidocaine was injected in the periurethral tissue at 4 and
8 o’clock, and the bulking agent was injected transurethrally
into the submucosa under cystoscopic control. Two to three
deposits were placed in the midurethra, and quantity was
decided by the surgeon’s judgement of coaptation. Needle
position was corrected if it was suspected to not be in the
mucosa or if there was bulking agent extravasion. If coapta-
tion was considered appropriate, the bladder was emptied.
Patients received a single-shot antibiotic prophylaxis with
trimethoprim-sulfamethoxazole and were discharged if post-
micturition residual volume was <100 ml. Evaluation was
performed 12 months postoperatively and a clinical control
without validated patient-orientated outcome measurements
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was conducted 6 weeks post-operatively. All adverse events
were monitored and registered. If the operation was not suc-
cessful, the women were offered a further injection after
6 weeks.
For statistical analysis, Graph Pad Prism version 5.0 for
Windows was used (Graph Pad, La Jolla, CA, USA) to
calculate Student’s t test and Mann–Whitney rank sum test.
Results
The four types of bulking agents used in this study were
collagen (n0312), ethylene vinyl alcohol (n0104), hyaluronic
acid (n054), and polyacrylamide hydrogel (n044), resulting
in a total number of 514 patients. Demographic data were
equally distributed in all four groups: age (median 79 years,
range 41–91), BMI (median 29 kg/m2, range 21–41 for poly-
acrylamide hydrogel and 19–41 for the other agents, respec-
tively), previous incontinence operations (median 1, range
0–4), number of injections (median 1, range 1–3), hospital
stay (median 2 days, range 1–3 except for one maximum stay
of 34 days in a patient in whom complications occurred after a
collagen injection), and operation time (median 10 min, range
10–25). Eighty percent of patients answered the questionnaire
in German, 18% in French, and 2% in English; 67% had SUI
and 33 %MUI. Despite one third of patients having MUI, the
complaint of SUI was predominant. Sixty-one patients were
lost to follow-up. For the agents used, the median changes in
maximum urethral closure pressure (MUCP) and the pad test
are shown in Fig. 1. VAS score as a measurement of self-
reported disturbance is illustrated in Fig. 2.
Analysis with the Mann–Whitney rank sum test for non-
normally distributed groups showed statistically significant
changes for MUCP, pad weight, and VAS before and after
bulking for all four agents used [all p<0.001, except for
MUCP with hyaluronic acid (p00.004) and for polyacryl-
amide hydrogel (p00.011))] Estimating that a pad test is
negative if ≤2 g, the exact percentage of objective success is
73.2 % of patients. In the subjective assessment of QoL after
bulking therapy, the domains general health and role limita-
tions of the KHQ were rated significantly better (Fig. 3),
whereas the other domains showed at least no deterioration
of QoL aspects.
The overall complication rate was low for all agents (col-
lagen 3.2 %, ethylene vinyl alcohol 5.7 %, hyaluronic acid
5.6 %, polyacrylamide hydrogel 0 %). The most serious side
effects were found for collagen, with two women having a
late-onset allergic reaction to collagen 3 and 6 weeks postop-
eratively, respectively, requiring analgetics and steroids. One
of these women had to be hospitalized for 34 days. Another
serious event (n01) was exposure of ethylene vinyl alcohol
after 2 years, requiring cystoscopic removal of the agent and
resulting in incontinence relapse. Further complications com-
prised: urinary retention for 1–7 days, treated with intermittent
catheterization using a self-lubricating catheter and ultrasound
check of residual urine after next micturition (collagen, n04);
simple urinary tract infection, treated with antibiotics (colla-
gen, n04 and ethylene vinyl alcohol, n03); temporary fre-
quency requiring anticholinergics for up to 2 weeks (ethylene
vinyl alcohol, n01 and hyaluronic acid, n01); worsening of
incontinence (hyaluronic acid, n02); tachyarrhythmia during
local anesthetic injection (before ethylene vinyl alcohol pro-
cedure, n01); blood-stained urine for 3 days (ethylene vinyl
alcohol, n01).
Discussion
This study found improvement of incontinence after bulking
therapy by applying subjective and objective outcomes in an
Fig. 1 Objective outcome: maximum urethral closure pressure (MUCP)
and pad test measurements before and after bulking therapy
Fig. 2 Subjective outcome: changes in visual analogue scale (VAS)
results of incontinence severity before and after bulking therapy
Int Urogynecol J (2013) 24:241–247 243
elderly population. Side-effects due to injections were few
and mild. The 514 women in this study showed a similar
demographic distribution for each of the four bulking agents
used. Thus, comparison of the results is not biased by
different patient collectives. Outcomes after bulking therapy
for four different bulking agents were studied. Although
ethylene vinyl alcohol (Tegress®) and hyaluronic acid
(Zuidex®) have been abandoned due to safety issues [15,
21, 22], their treatment outcomes were in line with the other
agents, and data are helpful for evaluating the bulking
principle.
Two types of outcomes are distinguished in this study:
objective measures (MUCP, pad test) and subjective assess-
ment (VAS, KHQ). Results for the objective measurements
were clear cut and showed a significant improvement.
MUCP might reflect the anatomic improvement with a
better coaptation of the urethral mucosa, and the pad test
indicates decreased urinary loss. The subjective assessment
revealed statistically significant improvements on the VAS
and several domains of the KHQ—namely, general health
and role limitations. The other domains were valued equally
or higher, yet not significantly, postoperatively. The KHQ
especially deals with the questions of how far women still
use incontinence pads and fear bad smell. Despite inconti-
nence being improved or cured, patients might fear urinary
leakage and thus use pads in everyday life. This might
explain why incontinence impact in the KHQ did not
improve. Patient-reported outcomes in incontinence ther-
apy are important, because objective parameters might
be necessary to verify improvement of urine leakage
when comparing interventions, but the impact on QoL
may differ substantially from objective measurements
[14]. Achievement of what is best for our patients by inves-
tigating and discussing treatment goals [11] is possible only if
we have a sound knowledge of subjective perceptions of a
therapy’s consequences.
The most recent Cochrane Review on bulking therapy
concluded not to be very helpful for clinical practice. How-
ever, injection therapy was considered useful as an option
for short-term symptomatic relief in selected patients with
comorbidities [10]. The minimal invasiveness; favorable
safety profile; high cure rates, at least in the short-
term; and improved QoL support the application of
bulking therapy [11, 14]. Moreover, prior bulking therapy
seems not to negatively affect outcomes if future anti-
incontinence surgery is needed [23]. Conversely, bulking
can be used after failed midurethral sling placement,
with a low cure rate but high patient satisfaction and no
significant complications [24].
The efficacy of the bulking principle in general is not yet
proven [25]. Continence, among other things, is achieved by
urethral mucosal coaptation established by the mucosa it-
self, submucosal vascular cushions, and smooth-muscle ac-
tivity [10]. Injection therapy into the urethral submucosa
creates cushions and is therefore meant to improve coapta-
tion [10]. Additionally, bulking agents are suggested to act
as a central filler volume, which lengthens the muscle fibers
and thus increases urethral sphincter strength [26]. Howev-
er, urodynamic data are limited, and according to the
Cochrane review, urodynamic measures should be included
Fig. 3 Subjective outcome:
King’s Health Questionnaire
domains before and after
bulking therapy
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in trials if the mechanism of any action is to be verified [10].
In this regard, our data, including MUCP measurements,
follow these recommendations, and our subjective outcomes
argue for efficacy of the bulking principle.
Although urethral bulking was thought to be particularly
helpful in women with a low MUCP (intrinsic sphincter
deficiency) [27], bulking is equally effective in both urethral
hypermobility and intrinsic sphincter deficiency [11, 14].
Endoscopic delivery of bulking agents under local anesthe-
sia is typical, yet a blind administration via special devices
may be considered beneficial [28]. The appropriate site for
injection is the midurethra [29], and the mode of deliv-
ery of the agent (periurethral vs. transurethral) leads to
similar outcomes but increased early complications if
administered periurethrally [10]. Two or three injections
are likely to be required to achieve a satisfactory result
[10]. A learning curve for mastering injection therapy
via an endoscope seems to be present [15]. Data on cost-
effectiveness of bulking are inconsistent, being cheaper than
tension-free vaginal tape (TVT) at least in the short term,
whereas economic modelling predicts a higher cost for
injection therapy [11].
Poor long-term results and the necessity of repeat injec-
tions hamper the use of bulking agents, and factors that
impact treatment success and durability are to be identified
[30]. The search for the ideal bulking agent aims at improv-
ing the bulking procedure. The properties of an ideal bulk-
ing agent should be durable, biocompatible, hypoallergenic,
deformable, nonimmunogenic, cause minimal inflammatory
and fibrotic response, and particles—usually suspended in a
biodegradable carrier gel—should be big enough to prevent
migration (>110 μm) [10, 14, 27]. Wide confidence inter-
vals and a diversion of outcome parameters complicate
comparison of agents in earlier studies [31]. In our study,
follow-up beyond 12 months was not feasible, as most
patients were referred for the bulking procedure only and
after the 1-year control patients were followed up by their
referring doctors. Thirty percent of patients (only ones who
were followed up by us or were re-referred) needed further
injection therapy after 12–18 months. Nevertheless, due to
this geriatric age group, the rate for reinjection might be even
higher: Patients may become seriously ill and unable to return
in the outpatient incontinence clinic for follow-up or may even
decease before incontinence reoccurs.
Silicone particles (Macroplastique™), calcium hydroxyl-
apatite (Coaptite™), ethylene vinyl alcohol (Uryx™),
carbon-coated zirconium beads (Durasphere™), porcine
dermal implant (Permacol™), and glutaraldehyde cross-
linked bovine collagen (Contigen™) show equal effective-
ness [10, 32–34], with variations in long- and short-term
outcomes [34–36]. Cure or improvement rates vary between
62 % and 80 % or 20 % and 86 %, depending on the source
used [9, 10, 37]. Autologous fat proved to be unsafe (one
death due to fat embolism), and a favorable outcome was
not found [10]. Polytetrafluoroethylene (Polytef™) made
from Teflon™ has been abandoned from clinical use be-
cause of particle migration [10]. Paraffin, ethylene vinyl
alcohol, and hyaluronic acid have been abandoned because
of safety issues [15, 21, 22]. Polyacrylamide hydrogel
(Bulkamid™) was specifically developed for urethral bulk-
ing, being biocompatible, nonbiodegradable, nonallergenic,
nonmigrational, atoxic, stable, and sterile [9, 15]. Its effica-
cy is proven, and its properties might circumvent drawbacks
of other agents mentioned [15, 38]. Further experimental
agents have been evaluated [10, 14, 39–41]. However, as in
our study a large number of patients showed similar out-
comes for all four different agents used, we demonstrate the
usefulness of bulking therapy regardless of the specific
agent.
Bulking agents have become popular, with a substantial
efficacy and low morbidity, but complications are not to be
ignored [14]. Although urethral bulking is considered to be
safe and simple [9, 14, 31], there are several reports on
complications caused by the different bulking agents, such
as urethral erosion [15], prolapse [42], and diverticula [43];
periurethral pseudocyst and mass formation [44]; retention;
de novo frequency; sterile and nonsterile abscess formation
[45]; hypersensitivity and urinary infection [15, 43]; granu-
loma formation and possibly carcinogenesis due to particle
migration [43]; need for endoscopic evacuation due to blad-
der outlet obstruction [46]. Treatment-related (minor) ad-
verse events were found to occur in a range of 22–50 %,
with UTI being the most common [15, 38]. Side effects
noted in our 514 patients are not in line with these data, as
we had very low and primarily minor side effects related to
bulking therapy.
The large number of patients is the major strength of our
study. Another strength is the assessment of both subjective
and objective outcomes, as subjective outcome might reflect
the patient’s goals more accurately than objective outcomes.
The use of validated tools underlines these findings.
Aweakness of this study is the use of four different types of
bulking agents; however, this was entirely due to availability
of substances and probably reflects the real-world practice,
with bulking agents appearing on and disappearing from the
market. A further weakness is patients who were lost to
follow-up (10.6 %). We do not know why these patients were
lost. It might be due to dissatisfaction, and if we count these
patients as still incontinent, the success rate of bulking might
be lower.
In conclusion, we can advocate bulking therapy for treating
SUI, as it is simple, safe, and shows both objective and
subjective improvement and relief in women, although it is
less effective than slings [47]. Our study might help support-
ing the use of bulking agents because of efficacy and minimal
invasiveness.
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